kalkinemedia.com
Cure8 news brief
Why This Matters
Some researchers and companies are developing antibiotic combinations that target MAP because MAP has been proposed as a contributor in a subset of Crohn's disease patients. New lab evidence that RHB-204 kills MAP could support further clinical study of a MAP-targeted therapy.
Who Should Pay Attention
Researchers studying MAP and Crohn's disease, clinicians interested in MAP-targeted experimental therapies, and patients following MAP-focused treatment research.
Study Snapshot
Story typeResearch news
Evidence typeEarly laboratory research
Source depthFull source text
What To Know
RedHill reported two independent in vitro laboratory studies showing its oral fixed-dose combination RHB-204 (clarithromycin + rifabutin + clofazimine) killed Mycobacterium avium subspecies paratuberculosis (MAP) across multiple strains, with killing comparable to the earlier RHB-104 formulation.
The filing highlights that effective MAP killing was observed in long-term intracellular cultures and in spot/phage assays, and that lower doses of two active ingredients achieved similar effects versus RHB-104. The report is based on company disclosures describing preclinical in vitro work (not clinical results).
RedHill positions RHB-204 as a Phase-2–ready, patent-protected, reduced-pill-burden oral regimen and notes regulatory designations (FDA Fast Track, Orphan Drug, QIDP; EU Orphan). The company suggests these data support further evaluation in MAP-positive Crohn's disease patients but the article does not report any human trial results.
If you follow MAP-targeted treatments, note that these findings are laboratory (in vitro) only and do not demonstrate safety or effectiveness in people. The company filing cites prior Phase 3 results for RHB-104 but this article does not present new clinical efficacy or safety data for RHB-204.
Keep In Mind
These are in vitro laboratory studies reported by the company; they do not show clinical benefit or safety in patients. Company filings and press releases can be promotional; independent peer-reviewed publication and clinical trials will be needed to confirm relevance to patient care.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationkalkinemedia.com
Indexed viaGoogle News
Source typeWeb article
PublishedNov 2, 2026, 12:15 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Research into protein could lead to new treatments
The study identifies a specific protein interaction that may underlie persistent inflammation; for people with Crohn’s and other inflammatory conditions this points to a potential new, more targeted treatment approach in...
Mesaconic acid delivery via biomaterials and engineered probiotics to the gut reduces inflammation in Crohn's Diseases mouse models
This preclinical study suggests raising mesaconate in the gut can reduce inflammation in mouse models of Crohn’s disease, using either an engineered probiotic or a zinc–mesaconate formulation—approaches that could...
A bile acid-GPBAR1 network supports anti-inflammatory and anti-fibrotic benefits of probiotics in colitis.
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...